NCT03009461View on ClinicalTrials.gov

Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

June 15, 2020

Study Completion Date

December 28, 2020

Conditions
HepatoCellular CarcinomaPortal Vein Thrombosis
Interventions
PROCEDURE

HAIC

Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.

DRUG

Sorafenib

400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.

Trial Locations (1)

100142

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER

NCT03009461 - Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis | Biotech Hunter | Biotech Hunter